Schade, N. published the artcileEvaluation of Novel Substituted Furopyridines as Inhibitors of Protein Kinases Related to Tau Pathology in Alzheimer’s Disease, Recommanded Product: (2-Methoxyphenyl)methanamine, the publication is Medicinal Chemistry (Sharjah, United Arab Emirates) (2021), 17(8), 844-855, database is CAplus and MEDLINE.
A novel furopyridines with various substitution patterns were synthezised and evaluated for protein kinases inhibition studies related to tau pathol. Furopyridine derivatives were synthesized and purified using column chromatog. The protein kinase inhibitory properties were determined in ATP-competition assays with determined affinity constants for the most active compounds The compounds were prepared in simple two-component reactions of substituted 1,4- dihydropyridines and resp. quinones to obtain various substitutions of the mol. furopyridine scaffold. The substituent effects on the determined kinase inhibitory properties of cdk1, cdk2, Fyn, JNK3 and gsk-3β are discussed. Various 3-substitutions were found most sensitive for the protein kinase inhibition depending on the length, nature and a substituent positioning within. These compounds were identified as inhibitors of several kinases as a tool to potentially combat the disease progress in a multitargeting approach.
Medicinal Chemistry (Sharjah, United Arab Emirates) published new progress about 6850-57-3. 6850-57-3 belongs to ethers-buliding-blocks, auxiliary class Amine,Benzene,Ether, name is (2-Methoxyphenyl)methanamine, and the molecular formula is C8H11NO, Recommanded Product: (2-Methoxyphenyl)methanamine.
Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem